Voya MidCap Opportunities Fund Q4 2025 Letter: Doximity Underperformance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: Yahoo Finance
- Fund Performance Analysis: The Voya MidCap Opportunities Fund underperformed its benchmark, the Russell Mid Cap Growth Index, in Q4 2025 primarily due to unfavorable stock selection, despite gains in the U.S. equity markets driven by moderating inflation and strong earnings.
- Doximity Stock Performance: Doximity, Inc. (NYSE:DOCS) recorded a one-month return of -7.21%, with its shares trading between $39.95 and $85.21 over the past 52 weeks, reflecting market caution regarding its future outlook.
- Position Impact: The overweight position in Doximity negatively impacted the fund's performance, particularly following the company's quarterly earnings report, which raised concerns due to cautious guidance and uncertainty stemming from recent healthcare policy changes.
- Investment Outlook: Despite geopolitical risks and policy uncertainties, fund managers maintain a cautiously optimistic outlook, believing that AI-driven innovation and sustained corporate capital expenditure could support future returns.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like DOCS with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on DOCS
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 62.75 USD with a low forecast of 50.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
10 Buy
4 Hold
1 Sell
Moderate Buy
Current: 38.730
Low
50.00
Averages
62.75
High
82.00
Current: 38.730
Low
50.00
Averages
62.75
High
82.00
About DOCS
Doximity, Inc. provides a digital platform for the United States medical professionals. It offers marketing, hiring, and workflow solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare companies. Its marketing solutions enable its pharmaceutical and health system customers to get the right content, services, and peer connections to the right medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms, enabling them to identify, connect with, and hire from its network of both active and passive medical professional candidates, who might otherwise be missed through traditional recruiting channels. Its workflow solutions include its telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and connect with patients and colleagues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
10 Small-Cap Stocks Set to Surge in 2026
- Small-Cap Stocks Performance: Small-cap stocks have started 2026 with strong momentum, indicating a positive trend in the market.
- Market Potential: Many of these companies are positioned to outperform the market, suggesting that the rally could continue.
Continue Reading
Telehealth Companies Face Significant Challenges Ahead
- Medicare Policy Tightening: With Medicare provisions expiring on January 31, only patients receiving telehealth services from healthcare facilities or in rural areas will be reimbursed, significantly reducing demand for telehealth services and impacting both Teladoc and Doximity's business performance.
- Teladoc's Weak Performance: Despite having a vast patient network, Teladoc's revenue growth has been slow and it remains unprofitable; with the impending Medicare changes, 2026 is expected to pose even greater challenges, suggesting investors should approach with caution.
- Doximity's Limited Profitability: While Doximity remains profitable, its revenue growth has slowed considerably and failed to meet market expectations, compounded by the fact that 80% of U.S. physicians are already on the platform, hindering its expansion and future sales growth prospects.
- Negative Market Reaction: Teladoc and Doximity's stock prices fell by 4.13% and 3.00% respectively, reflecting investor pessimism regarding both companies' future performance, which may lead to further market sell-offs.
Continue Reading